Kelly Lisbakken

Managing Director, Healthcare Investment Banking

Kelly Lisbakken is a Managing Director in the Healthcare Investment Banking Group at Wedbush PacGrow focusing on Biotechnology and Specialty Pharmaceuticals. Ms. Lisbakken joined Pacific Growth Equities in 2004 and has completed over 220 transactions with the firm raising over $22 billion. Prior to Wedbush, Kelly worked at ICOS (now part of Eli Lilly) on Cialis and the PDE4 program. She is also a member of the Board of Directors for the Retinal Degeneration Fund, a wholly owned, 501(c)(3)not-for-profit subsidiary focused on making venture philanthropy investments to further the mission of the Foundation Fighting Blindness. Kelly holds an AB in Molecular Biology from Princeton University where she completed her thesis under the direction of Dr. Thomas Shenk, the Elkins Professor in the Life Sciences and former board member of Merck & Co.